- Home
- EMF vs AMRN Comparison
EMF vs AMRN Comparison
Compare EMF & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMF | AMRN |
|---|---|---|
| Founded | 1987 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.5M | 339.8M |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | EMF | AMRN |
|---|---|---|
| Price | $16.34 | $13.88 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 29.3K | ★ 84.3K |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 6.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.58 | $7.08 |
| 52 Week High | $12.67 | $20.90 |
Technical Indicators
Market Signals| Indicator | EMF | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 36.01 | 32.16 |
| Support Level | $16.20 | $13.64 |
| Resistance Level | $16.62 | $14.49 |
| Average True Range (ATR) | 0.23 | 0.76 |
| MACD | -0.12 | -0.11 |
| Stochastic Oscillator | 10.13 | 11.73 |
Price Performance
Historical ComparisonAbout EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.